Trustco Bank Corp N Y Has $1.32 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Trustco Bank Corp N Y reduced its position in Eli Lilly and Company (NYSE:LLY) by 8.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,704 shares of the company’s stock after selling 165 shares during the period. Eli Lilly and Company comprises about 1.4% of Trustco Bank Corp N Y’s holdings, making the stock its 23rd largest position. Trustco Bank Corp N Y’s holdings in Eli Lilly and Company were worth $1,315,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Knightsbridge Asset Management LLC boosted its stake in shares of Eli Lilly and Company by 1.9% during the 4th quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company’s stock worth $628,000 after acquiring an additional 15 shares in the last quarter. Centerpoint Advisory Group bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $514,000. Kentucky Trust Co bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $834,000. CSM Advisors LLC boosted its stake in shares of Eli Lilly and Company by 30.6% during the 4th quarter. CSM Advisors LLC now owns 1,045 shares of the company’s stock worth $807,000 after acquiring an additional 245 shares in the last quarter. Finally, Proficio Capital Partners LLC boosted its stake in shares of Eli Lilly and Company by 30.2% during the 4th quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company’s stock worth $5,202,000 after acquiring an additional 1,562 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $757.23 on Monday. The stock has a 50 day moving average of $797.84 and a two-hundred day moving average of $805.69. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The company has a market capitalization of $717.65 billion, a P/E ratio of 64.67, a P/E/G ratio of 1.40 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same quarter in the prior year, the business posted $2.58 EPS. Eli Lilly and Company’s revenue was up 45.2% compared to the same quarter last year. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, May 16th. This represents a $6.00 annualized dividend and a dividend yield of 0.79%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 48.82%.

Wall Street Analyst Weigh In

LLY has been the subject of several recent analyst reports. The Goldman Sachs Group upgraded Eli Lilly and Company from a “neutral” rating to a “buy” rating and decreased their price target for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. HSBC downgraded Eli Lilly and Company from a “buy” rating to a “reduce” rating and decreased their price target for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. Cantor Fitzgerald started coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 target price for the company. Wells Fargo & Company restated an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Finally, Citigroup decreased their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,011.37.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.13% of the stock is owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.